File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/FJC.0000000000000194
- Scopus: eid_2-s2.0-84934900027
- PMID: 26070128
- WOS: WOS:000356370300001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia–Reperfusion Injury?
Title | Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia–Reperfusion Injury? |
---|---|
Authors | |
Keywords | Nucleoside transporters Adenosine Cardioprotection Ischemia |
Issue Date | 2015 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/ |
Citation | Journal of Cardiovascular Pharmacology, 2015, v. 65 n. 6, p. 517-521 How to Cite? |
Abstract | The cardioprotective effects of adenosine and adenosine receptor agonists have been studied extensively. However, their therapeutic outcomes in ischemic heart disease are limited by systemic side effects such as hypotension, bradycardia, and sedation. Equilibrative nucleoside transporter (ENT) inhibitors may be an alternative. By reducing the uptake of extracellular adenosine, ENT1 inhibitors potentiate the cardioprotective effect of endogenous adenosine. They have fewer systemic side effects because they selectively increase the extracellular adenosine levels in ischemic tissues undergoing accelerated adenosine formation. Nonetheless, long-term inhibition of ENT1 may adversely affect tissues that have low capacity for de novo nucleotide biosynthesis. ENT1 inhibitors may also affect the cellular transport, and hence the efficacy, of anticancer and antiviral nucleoside analogs used in chemotherapy. It has been proposed that ENT4 may also contribute to the regulation of extracellular adenosine in the heart, especially under the acidotic conditions associated with ischemia. Like ENT1 inhibitors, ENT4 inhibitors should work specifically on ischemic tissues. Theoretically, ENT4 inhibitors do not affect tissues that rely on ENT1 for de novo nucleotide synthesis. They also have no interaction with anticancer and antiviral nucleosides. Development of specific ENT4 inhibitors may open a new avenue in research on ischemic heart disease therapy. |
Persistent Identifier | http://hdl.handle.net/10722/211898 |
ISSN | 2023 Impact Factor: 2.6 2023 SCImago Journal Rankings: 0.610 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, C | - |
dc.contributor.author | Leung, GPH | - |
dc.date.accessioned | 2015-07-21T02:15:20Z | - |
dc.date.available | 2015-07-21T02:15:20Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Journal of Cardiovascular Pharmacology, 2015, v. 65 n. 6, p. 517-521 | - |
dc.identifier.issn | 0160-2446 | - |
dc.identifier.uri | http://hdl.handle.net/10722/211898 | - |
dc.description.abstract | The cardioprotective effects of adenosine and adenosine receptor agonists have been studied extensively. However, their therapeutic outcomes in ischemic heart disease are limited by systemic side effects such as hypotension, bradycardia, and sedation. Equilibrative nucleoside transporter (ENT) inhibitors may be an alternative. By reducing the uptake of extracellular adenosine, ENT1 inhibitors potentiate the cardioprotective effect of endogenous adenosine. They have fewer systemic side effects because they selectively increase the extracellular adenosine levels in ischemic tissues undergoing accelerated adenosine formation. Nonetheless, long-term inhibition of ENT1 may adversely affect tissues that have low capacity for de novo nucleotide biosynthesis. ENT1 inhibitors may also affect the cellular transport, and hence the efficacy, of anticancer and antiviral nucleoside analogs used in chemotherapy. It has been proposed that ENT4 may also contribute to the regulation of extracellular adenosine in the heart, especially under the acidotic conditions associated with ischemia. Like ENT1 inhibitors, ENT4 inhibitors should work specifically on ischemic tissues. Theoretically, ENT4 inhibitors do not affect tissues that rely on ENT1 for de novo nucleotide synthesis. They also have no interaction with anticancer and antiviral nucleosides. Development of specific ENT4 inhibitors may open a new avenue in research on ischemic heart disease therapy. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/ | - |
dc.relation.ispartof | Journal of Cardiovascular Pharmacology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Nucleoside transporters | - |
dc.subject | Adenosine | - |
dc.subject | Cardioprotection | - |
dc.subject | Ischemia | - |
dc.title | Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia–Reperfusion Injury? | - |
dc.type | Article | - |
dc.identifier.email | Leung, GPH: gphleung@hkucc.hku.hk | - |
dc.identifier.authority | Leung, GPH=rp00234 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1097/FJC.0000000000000194 | - |
dc.identifier.pmid | 26070128 | - |
dc.identifier.pmcid | PMC4461397 | - |
dc.identifier.scopus | eid_2-s2.0-84934900027 | - |
dc.identifier.hkuros | 244764 | - |
dc.identifier.volume | 65 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 517 | - |
dc.identifier.epage | 521 | - |
dc.identifier.isi | WOS:000356370300001 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0160-2446 | - |